Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 34,158 | 54,651 | 86,722 | 4,936 | 0 |
| Marketable Securities | 61,931 | 51,624 | 19,145 | 23,971 | 0 |
| TOTAL | $99,711 | $110,593 | $109,816 | $30,624 | $0 |
| Non-Current Assets | |||||
| PPE Net | 376 | 400 | 418 | 442 | N/A |
| Other Non-Current Assets | 88 | 324 | 88 | 2,232 | 0 |
| TOTAL | $464 | $724 | $506 | $2,674 | $N/A |
| Total Assets | $100,175 | $111,317 | $110,322 | $33,298 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,886 | 1,669 | 2,322 | 1,658 | 0 |
| Accrued Expenses | 3,424 | 3,179 | 2,627 | 2,540 | 0 |
| TOTAL | $5,310 | $4,848 | $4,949 | $4,198 | $0 |
| Non-Current Liabilities | |||||
| TOTAL | $167 | $173 | $179 | $184 | $N/A |
| Total Liabilities | $5,477 | $5,021 | $5,128 | $4,382 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,352 | 4,331 | 4,320 | N/A | N/A |
| Common Shares | 18 | 18 | 17 | 1 | 0 |
| Retained earnings | -84,595 | -72,172 | -61,968 | -54,753 | 0 |
| Other shareholders' equity | 24 | 48 | -16 | 77,796 | 0 |
| TOTAL | $94,698 | $106,296 | $105,194 | $28,916 | $0 |
| Total Liabilities And Equity | $100,175 | $111,317 | $110,322 | $33,298 | $0 |